USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: Synaptic Pharmaceutical Corp.
City: Paramus
State: NJ
Zip+4: 07652
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (201) 261-1331

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,028,750.00 16
SBIR Phase II $2,607,846.00 5

Award List:

CLONING OF THE SEROTONIN 5-HT1B AND 5-HT1D RECEPTORS

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
The 5-ht1b and 5-ht1d receptors appear to play a significantrole in at least four medically important processes: thermoregulation, appetite control, anxiety, and obsessive-compulsive disorders. these receptors are difficult to study due to their low density, interference by other serotonin-receptor… More

ASSAY SYSTEM FOR CLONED GI-COUPLED RECEPTORS

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00

EXPRESSION CLONING OF THE DOPAMINE DI RECEPTOR

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Richard Weinshank
Award Amount: $50,000.00

CLONING OF THE SEROTONIN 5-HT1P RECEPTOR

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Theresa A Branchek
Award Amount: $50,000.00

ASSAY SYSTEM FOR CLONED GI-COUPLED RECEPTORS

Award Year / Program / Phase: 1991 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $400,293.00
Abstract:
Molecular cloning and heterologous expression of neurotransmitter receptor genes provide a means to study these sites of drug action free from the complexities of intact neural tissue. these heterologous expression systemscan then be used as assay systems in the development of new therapeutic… More

CLONING OF THE SEROTONIN 5-HT1P RECEPTOR

Award Year / Program / Phase: 1991 / SBIR / Phase II
Agency: HHS
Principal Investigator: Theresa A Branchek
Award Amount: $479,956.00
Abstract:
The serotonin 5-ht1p receptor has been extensively characterized in the enteric nervous system where it functions in the regulation of gastrointestinal motility. in addition, 5-ht1p-like binding sites have been discovered in the pericardium and endocardium of the heart, the innervation of the skin,… More

EXPRESSION CLONING OF THE DOPAMINE DI RECEPTOR

Award Year / Program / Phase: 1991 / SBIR / Phase II
Agency: HHS
Principal Investigator: Richard Weinshank
Award Amount: $477,597.00
Abstract:
Dopaminergic neurotransmission plays a significant role in psychiatric and extrapyramidal disorders, endocrine function, and vasodilation. to better understand the dopamine d1 receptor as a potential site for drug development, it is planned to identify and characterize the receptor gene by… More

MOLECULAR CLONING OF POIATE RECEPTOR SUBTYPES

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Paul Hartig
Award Amount: $50,000.00
Abstract:
Opiate receptors, which are important pharmacological targets for analgesia and for the control of drug addiction,have not been cloned and their amino acid sequences are unknown. recent work indicates that several opiate receptorsubtypes are coupled to g protein second messenger systems. therefore,… More

CHARACTERIZATION OF CLONIDINE DISPLACING SUBSTANCE

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Charles Gluchowski
Award Amount: $50,000.00
Abstract:
Recent molecular pharmacological studies have indentified a new receptor class which resembles alpha 2 adrenoceptors but because of subtle difference has been named by a variety of descriptors including imidazole receptors. these receptors have been implicated as being important in controlling… More

FUNCTIONAL ASSAY SYSTEMS FOR HUMAN ADRENERGIC RECEPTORS

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Carlos Forray
Award Amount: $50,000.00
Abstract:
Alpha-1 adrenergic drugs have recently shown great potential in the treatment of bph. the existence of receptor heterogeneity within the alpha-1 adrenoceptors suggests the possibility of improving drugs by refining their subtype selectivity. molecular cloning of three subtypes of the a1 receptors… More

NPY-Like Agonists and Antagonists for CNS YL Receptors

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Mary W. Walker
Award Amount: $50,000.00
Abstract:
Neuropeptide Y (NPY) activates at least three receptor subtypes with central and peripheral localization (Y1, Y2, and Y3). The human Y1 receptor, linked to various CNS disorders including anxiety, depression, bulimia, and cocaine addition, has been cloned and targeted by Synaptic Pharmaceutical… More

GABA Transport Assay

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Laurence A. Borden
Award Amount: $50,000.00
Abstract:
GABA transport inhibitors have recently shown promise as anticonvulsants. The cloning of two novel GABA transporters, in addition to the previously cloned neuronal transporter, suggests a diversity of therapeutic targets. However, it is not known whether an effective drug should be a substrate for… More

Rational Design Neuropeptide Y Therapeutics

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: John A. Salon
Award Amount: $50,000.00

Camp-Stimulatory Serotonin Receptors

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jonathan Bard
Award Amount: $78,750.00
Abstract:
Activation of a subset of serotonin receptors evokes physiological responses characteristic ofadenylate cyclase stimulation in a wide variety of tissues: neuronal depolarization, relaxation of smoothmuscle, and positive inotropy in cardiac muscle. The receptor subtypes will serve as drug targets… More

Antisense Strategy for Determining Receptor Function

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: Theresa Branchek
Award Amount: $75,000.00
Abstract:
The use of oligonucleotide probes to modulate the synthesis of protein molecules has hadimportant implications in understanding the growth of viruses and expression of oncogenes. Morerecently, antisense strategies have been employed in studies examining the nervous system. Theapplications of this… More

Rational Design Neuropeptide Y Therapeutics

Award Year / Program / Phase: 1994 / SBIR / Phase II
Agency: HHS
Principal Investigator: John A. Salon
Award Amount: $500,000.00
Abstract:
Neuropeptide Y (NPY) has been implicated in a variety of pathological conditions including cardiovascular and respiratory abnormalities, Parkinson's disease, depression and Alzheimer's disease. A program of rational drug design to develop non-peptide NPY analogs for intervention in these disorders… More

New Pharmacological Tools for Alpha Adrenergic Receptors

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: John Wetzel
Award Amount: $75,000.00

New Pharmacological Tools for Alpha Adrenergic Receptors

Award Year / Program / Phase: 1996 / SBIR / Phase II
Agency: HHS
Principal Investigator: John Wetzel
Award Amount: $750,000.00
Abstract:
Alpha adrenoceptors serve numerous functions throughout the peripheral and central nervoussystems. Chemical modulators of these receptors have a variety of potential therapeutic applications,including treatments for benign prostatic hyperplasia, hypertension, pain and glaucoma. Although sixalpha… More

REPORTER GENE RECEPTOR SCREENING SYSTEM

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $100,000.00

DESIGN AND SYNTHESIS OF BIASED COMBINATORIAL LIBRARIES

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $100,000.00

INNOVATIVE APPROACH TO NPY Y2 ANTAGONIST DISCOVERY

Award Year / Program / Phase: 1997 / SBIR / Phase I
Agency: HHS
Principal Investigator: Noble, stewart a
Award Amount: $100,000.00